Charles Schwab Investment Management Inc. Invests $183,000 in Chimerix, Inc. (NASDAQ:CMRX)

Charles Schwab Investment Management Inc. purchased a new stake in Chimerix, Inc. (NASDAQ:CMRX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 52,657 shares of the biopharmaceutical company’s stock, valued at approximately $183,000.

Several other institutional investors have also recently added to or reduced their stakes in CMRX. Stoneridge Investment Partners LLC grew its stake in shares of Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 8,134 shares during the last quarter. Palumbo Wealth Management LLC purchased a new stake in shares of Chimerix during the fourth quarter worth approximately $221,000. Valeo Financial Advisors LLC lifted its holdings in shares of Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 64,420 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after purchasing an additional 496,823 shares during the period. Finally, Peapod Lane Capital LLC purchased a new position in Chimerix in the 4th quarter valued at $2,626,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CMRX shares. Jefferies Financial Group restated a “hold” rating and set a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. HC Wainwright reiterated a “neutral” rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com assumed coverage on shares of Chimerix in a research report on Monday. They issued a “hold” rating for the company. Finally, Wedbush reiterated a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

Chimerix stock opened at $8.50 on Wednesday. The company has a market cap of $797.33 million, a P/E ratio of -9.04 and a beta of 0.32. Chimerix, Inc. has a one year low of $0.75 and a one year high of $8.53. The business has a fifty day moving average of $6.04 and a two-hundred day moving average of $3.23.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. Sell-side analysts predict that Chimerix, Inc. will post -0.99 EPS for the current year.

Insider Buying and Selling at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 20,760 shares of company stock valued at $91,175. Corporate insiders own 13.10% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.